AlphAIAlphAI — Financial news for AI agents
securities.ioOCT 53 min read$FRSH

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

Original reporting
securities.io
Published Oct 5, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$FRSH
Bullish
high confidence
Mentioned
$FRSH · $RGEN · $BLFS
Relevance
8/10
AlphAI data visualization · based on securities.io
Decision brief

The 30-second read

$FRSHBullishHigh
01

Why it matters

The index addition adds passive demand for Freshworks, while the acquisition creates upside for Repligen and sets a clear valuation for BioLife.

02

Market read

Three U.S. listed companies are directly affected by index rebalancing and a sizable M&A deal, offering clear trading opportunities.

03

What to watch

Potential integration risks for Repligen and the cash drain from the $1.5 billion deal.

Relevance 8/10Novelty 8/10Timing: effective pre‑market Oct 8, 2026

Background

S&P Dow Jones announced index changes and Repligen disclosed a $1.5 billion acquisition of BioLife, with detailed terms and expected synergies.

Company-level read

Ticker impact

$FRSHBullishHigh confidence
Context

Freshworks will be added to the S&P SmallCap 600 on Oct 8, likely boosting demand from index funds.

Expected impact

likely upward as passive buying commences

Evidence & confidence

Index inclusion drives automatic buying and visibility.

$RGENBullishHigh confidence
Context

Repligen announced a definitive agreement to acquire BioLife for $1.5 billion, a material M&A transaction.

Expected impact

upward pressure from premium and expected earnings accretion

Evidence & confidence

Deal adds cash and stock consideration, with synergies and EPS accretion.

$BLFSNeutralHigh confidence
Context

BioLife is being acquired by Repligen and will be removed from the S&P SmallCap 600.

Expected impact

price will align with deal consideration

Evidence & confidence

Acquisition terms set a clear valuation floor.

Market effects

Sector

IT sector gains exposure to Freshworks; biotech/healthcare sees consolidation via Repligen‑BioLife.

Regional

U.S. small‑cap indices adjust composition; modest impact on broader market.

Global

Limited to U.S. equity markets; no direct global macro effect.

Counterpoint

What could challenge this read

If the acquisition faces regulatory delays, RGEN could see short‑term volatility.

Key entities

  • Company
    Freshworks Inc.

    Software SaaS provider added to S&P SmallCap 600.

  • Company
    Repligen Corp.

    Biotech firm acquiring BioLife for $1.5 billion.

  • Company
    BioLife Solutions Inc.

    Target of Repligen acquisition, removed from index.

Read at source← All news

Related articles

OCT 6
$FRSHMed

Why Are Freshworks (FRSH) Shares Soaring Today

Freshworks (FRSH) shares rose 5.4% in pre-market trading after S&P Dow Jones Indices announced its addition to the S&P SmallCap 600, effective October 8, 2026. The company will replace BioLife Solutions, which is being acquired by Repligen. Freshworks is up 20.6% year-to-date, reaching a 52-week high of $13.99. However, long-term investors have seen a decline in value over five years.

financialcontent.com2 min
OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min